Revenue from Contracts with Customers

Disaggregated Revenues

The following table provides information about disaggregated revenue by major product line and primary geographic market (in thousands):



	Three Months Ended September 30, 2019								Nine Months Ended September 30, 2019
	Americas		Europe and Middle East		Asia Pacific		Total		Americas		Europe and Middle East		Asia Pacific		Total
Product revenue:
Instruments	$	5,823	$	1,577	$	637	$	8,037	$	11,609	$	4,066	$	1,620	$	17,295
Consumables	8,872		3,040		824		12,736		25,241		9,084		2,331		36,656
In vitro diagnostic kits	776		1,670		71		2,517		1,852		5,350		243		7,445
Total product revenue	15,471		6,287		1,532		23,290		38,702		18,500		4,194		61,396
Service revenue	2,004		841		214		3,059		5,965		2,136		572		8,673
Total product and service revenue	17,475		7,128		1,746		26,349		44,667		20,636		4,766		70,069
Collaboration revenue	4,255		—		—		4,255		18,568		—		—		18,568
Total revenues	$	21,730	$	7,128	$	1,746	$	30,604	$	63,235	$	20,636	$	4,766	$	88,637



	Three Months Ended September 30, 2018								Nine Months Ended September 30, 2018
	Americas		Europe and Middle East		Asia Pacific		Total		Americas		Europe and Middle East		Asia Pacific		Total
Product revenue:
Instruments	$	3,696	$	1,149	$	584	$	5,429	$	9,512	$	4,189	$	1,890	$	15,591
Consumables	7,808		2,633		699		11,140		20,770		7,882		2,126		30,778
In vitro diagnostic kits	783		1,687		77		2,547		2,382		4,600		252		7,234
Total product revenue	12,287		5,469		1,360		19,116		32,664		16,671		4,268		53,603
Service revenue	1,582		641		114		2,337		4,383		1,589		307		6,279
Total product and service revenue	13,869		6,110		1,474		21,453		37,047		18,260		4,575		59,882
Collaboration revenue	7,163		—		—		7,163		16,818		—		—		16,818
Total revenues	$	21,032	$	6,110	$	1,474	$	28,616	$	53,865	$	18,260	$	4,575	$	76,700

Contract balances and remaining performance obligations

Contract liabilities are comprised of the current and long-term portions of deferred revenue of $5.3 million and $11.5 million as of September 30, 2019 and December 31, 2018, respectively, and customer deposits of $6.5 million and $8.2 million as of September 30, 2019 and December 31, 2018, respectively, included within the condensed consolidated balance sheets. Total contract liabilities decreased by $8.0 million for the nine months ended September 30, 2019 as a result of the recognition of previously deferred revenue and customer deposits of $23.9 million for the completion of certain performance obligations during the period, partially offset by cash payments received of $16.0 million related to our collaborations and service contracts. The Company did not record any contract assets as of September 30, 2019.

As of September 30, 2019, unsatisfied or partially unsatisfied performance obligations related to the collaboration agreement with Lam Research Corporation (“Lam”) were $6.0 million and are expected to be completed by the first half of 2020. Performance obligations related to undelivered products and service contracts as of September 30, 2019 were $5.7 million and are expected to be completed over the term of the related contract or as products are delivered.